NWI Management LP Boosts Stake in Insmed Incorporated (NASDAQ:INSM)

NWI Management LP increased its stake in Insmed Incorporated (NASDAQ:INSM) by 186.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 279,000 shares of the biopharmaceutical company’s stock after purchasing an additional 181,460 shares during the period. Insmed makes up approximately 0.8% of NWI Management LP’s portfolio, making the stock its 19th biggest holding. NWI Management LP’s holdings in Insmed were worth $19,262,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of INSM. Capital CS Group LLC purchased a new position in shares of Insmed in the 4th quarter worth $586,000. Park Avenue Securities LLC raised its stake in Insmed by 42.1% during the fourth quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company’s stock valued at $549,000 after purchasing an additional 2,358 shares in the last quarter. Atomi Financial Group Inc. raised its position in Insmed by 6.6% during the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company’s stock valued at $1,710,000 after purchasing an additional 1,526 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 183 shares during the last quarter. Finally, Avior Wealth Management LLC bought a new position in shares of Insmed in the fourth quarter worth about $157,000.

Insmed Stock Down 3.0%

INSM opened at $65.71 on Wednesday. The company has a market cap of $11.95 billion, a PE ratio of -11.75 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The firm has a 50 day moving average price of $72.17 and a 200 day moving average price of $73.26.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.06) EPS. Sell-side analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus decreased their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. UBS Group lowered their price target on Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a report on Friday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Jefferies Financial Group started coverage on shares of Insmed in a report on Tuesday. They issued a “buy” rating and a $105.00 target price on the stock. Finally, Guggenheim restated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

Insiders Place Their Bets

In related news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the sale, the chief financial officer now owns 118,863 shares in the company, valued at approximately $9,545,887.53. The trade was a 13.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the transaction, the chief executive officer now owns 334,186 shares in the company, valued at $27,079,091.58. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 88,232 shares of company stock worth $6,868,473 in the last quarter. 3.00% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.